Drug Repurposing Stakeholders Say FDA Should Act
Drug repurposing Stakeholders say FDA should weigh public evidence and commercial gaps carefully, and the agency is now asking them directly. On May 11, 2026, FDA opened docket FDA-2026-N-4492 to gather input on priority diseases and candidates while stressing that the work builds on existing statutory and agency authorities.
Contents10 sections
Key Takeaways
- FDA opened a Request for Information on drug repurposing for unmet medical needs (docket FDA-2026-N-4492), with comments due June 11, 2026.
- The agency framed the effort as building on existing authorities, including the MODERN Labeling Act of 2020 and Project Renewal.
- FDA is targeting approved drugs that may lack commercial incentive for a supplemental new-use application.
- Priority areas flagged include metabolic disease, neurodegeneration, women's and men's health, substance use disorders, and rare diseases.
FDA drug-repurposing RFI at a glance
| Field | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Action | Request for Information; public docket |
| Docket | FDA-2026-N-4492 |
| Federal Register | May 12, 2026 (91 FR 25897) |
| Comment deadline | June 11, 2026 |
| Focus | New uses for FDA-approved drugs with limited commercial incentive for supplements |
| Cited authorities | BPCA; MODERN Labeling Act of 2020; Project Renewal; NIH collaboration direction |
What is FDA asking stakeholders to provide?
In FDA's May 11, 2026 press announcement, the agency said it wants information on priority disease areas and potential candidates for drug repurposing. The focus is strongest where scientific data may support a new use, but commercial incentives to pursue approval appear limited.
FDA listed three candidate buckets: uses with enough evidence to support a potential new indication; uses with promising preliminary clinical data such as case reports or observational studies; and uses with promising preclinical signals, including from artificial intelligence and machine learning tools.
The agency also asked for ideas on innovative ways to find repurposing opportunities and for barriers that limit development or use when there is little commercial incentive to update labeling based on publicly available evidence.
How does the Federal Register notice define the scope?
The Federal Register notice published May 12, 2026 repeats that FDA wants help refining how it considers and evaluates repurposing candidates. It concentrates on approved drugs for which there appears to be no commercial interest in adding a new use through a supplemental application.
For that focus set, FDA described criteria that include compelling scientific evidence of effectiveness for the new use, the same dosage form and route as an approved indication, and a comparable safety profile across the relevant populations. The notice also invites candidates that do not meet every criterion but have promising preliminary data for an unmet need.
Initial priority chronic disease areas named in the notice include metabolic diseases, neurodegenerative conditions, women's health conditions such as menopause-related conditions, men's health conditions such as testosterone deficiency, substance use disorders, and rare diseases.
What does "act within its authority" mean in FDA's own framing?
FDA did not cast the RFI as a request for new legislation. Instead, the May announcement says the effort builds on existing authorities and initiatives that already support labeling updates when science supports them.
Those include the Best Pharmaceuticals for Children Act, the Making Objective Drug Evidence Revisions for New (MODERN) Labeling Act of 2020, and Project Renewal. Congress's MODERN Labeling Act of 2020 (H.R. 5668) was designed to help FDA update outdated labels for certain generic drugs when updates would provide a public health benefit.
That statutory framing matters for stakeholders who want FDA to move on evidence without creating new exclusivity traps or commercial disincentives. FDA's own materials emphasize using authorities already on the books rather than inventing a parallel approval track.
How does Project Renewal fit the labeling update model?
FDA's Project Renewal page describes a public health initiative to update prescribing information for certain older oncology drugs so labels stay clinically meaningful and scientifically current. The program reviews publicly available evidence and has already supported labeling updates for drugs including fludarabine phosphate, temozolomide, and capecitabine.
Project Renewal is not a blank check for every off-label use. It is a process for evaluating published evidence against FDA's labeling standards. In the May RFI, FDA pointed to that model as one existing way the agency already updates labels when evidence supports change.
What role does NIH / NCATS already play in repurposing?
FDA also linked the RFI to a September 2025 Make Our Children Healthy Again strategy direction to work with NIH on strengthening use of repurposed drugs for chronic disease and harmonizing authorization processes through collaborative trial designs aimed at FDA approval.
Separately, NIH's National Center for Advancing Translational Sciences (NCATS) drug-repurposing program has long framed repurposing as a way to shorten development by starting from compounds that already have human data. NCATS resources include compound libraries, screening tools, and programs designed to move existing molecules into new uses faster than de novo discovery.
That NIH layer is relevant to the commercial-incentive problem FDA named: many promising new uses lack a sponsor willing to fund a supplemental application, even when public data exist.
What should sponsors and patient groups watch next?
The comment window closed June 11, 2026. The next signal is how FDA uses the docket to refine candidate selection, evidence expectations, and any collaboration model with NIH or CMS. Until then, the operative message from FDA's own notice is narrower than a new mandate: gather public evidence, stay inside existing authorities, and avoid leaving scientifically supported uses stranded because no company wants to file a supplement.
For adjacent U.S. regulatory reading on NovaPharma, see FDA human-factors guidance for marketing submissions, FDA's Salmonella moringa leaf powder recall, and why sepsis AI algorithms need real-time data.
Frequently Asked Questions
What did FDA announce about drug repurposing in May 2026?
On May 11, 2026, FDA announced a request for information on drug repurposing to address unmet medical needs. The Federal Register notice for docket FDA-2026-N-4492 opened a public comment period through June 11, 2026, focused on priority disease areas and candidates where commercial incentives to file a supplemental application appear limited.
Which existing authorities does FDA say support drug-repurposing labeling updates?
FDA said the effort builds on existing authorities and initiatives, including the Best Pharmaceuticals for Children Act, the Making Objective Drug Evidence Revisions for New (MODERN) Labeling Act of 2020, and Project Renewal, which has updated labeling for several oncology drugs using publicly available evidence.
What feedback is FDA seeking from stakeholders?
FDA is asking patients, clinicians, researchers, and other stakeholders for priority disease areas and repurposing candidates, including cases with sufficient evidence, promising preliminary clinical data, or promising preclinical signals. It also seeks input on barriers that limit development or use of repurposed drugs when commercial incentives to pursue labeling changes are weak.
Primary Sources
- FDA: Advances drug repurposing to address unmet medical needs (May 11, 2026)
- Federal Register / GovInfo: Drug Repurposing for Unmet Medical Needs; RFI (May 12, 2026)
- Congress.gov: MODERN Labeling Act of 2020 (H.R. 5668)
- FDA Oncology Center of Excellence: Project Renewal
- NCATS / NIH: Drug repurposing program
